NAD+ Cost Breakdown: Compounded Telehealth vs IV Clinic

The question patients ask most often about NAD+ is not what it does. It is what it costs, why the clinic IV price is so much higher than the telehealth subcutaneous price, and whether one format is actually better than the other or whether the price reflects something other than clinical value.

This article walks through the honest math: typical clinic IV pricing, typical telehealth subcutaneous monthly cost, what insurance does and does not cover, and where the structural cost differences come from. The goal is not to argue for one format. It is to give patients a clear picture so they can make a decision that fits their actual goal.

What an IV session costs at a clinic

IV NAD+ pricing varies by region and clinic tier, but a representative range across US wellness and longevity clinics looks like this:

• Boutique wellness clinic, midwestern metro: $300 to $500 per session for 500 to 750 mg
• Regional concierge clinic, coastal metro: $500 to $800 per session for 750 to 1,000 mg
• Premium longevity practice, major metro: $800 to $1,200 per session for 1,000 mg, often bundled with concierge consultation

A standard session runs 60 to 90 minutes. Most clinics charge per session, not monthly. A patient who comes weekly for four weeks at the regional concierge tier will spend $2,000 to $3,200 in a month.

What is included in that price: the active ingredient, the saline carrier, the IV setup, nursing time to monitor the infusion, the clinic chair, and overhead. What is usually not included: ongoing clinician oversight between sessions, prescription review, or labs.

What telehealth subcutaneous monthly cost looks like

Compounded subcutaneous NAD+ delivered through a licensed telehealth clinician is structured around a flat monthly fee rather than per-session billing. Representative ranges:

• Entry telehealth program: $200 to $300 per month, typically 50 to 100 mg twice weekly
• Standard telehealth program: $300 to $400 per month, typically 100 mg twice or three times weekly
• High-dose telehealth program: $400 to $600 per month, with per-session dose at 150 to 200 mg

Inside that flat fee: clinician onboarding visit, prescription, compounded medication from a licensed 503A pharmacy, shipping, syringes and supplies, and ongoing check-in cadence with the prescribing clinician.

A patient on a standard program receiving 100 mg twice weekly accumulates roughly 800 mg in a month — comparable in total milligrams to a single IV session at most clinics, delivered across eight sessions instead of one, at one-quarter to one-fifth of the cost.

The insurance reality

For most patients seeking NAD+ for energy, recovery, sleep, or longevity goals, insurance does not cover it.

Major medical carriers categorize NAD+ as a wellness or anti-aging intervention. The CPT and J-codes that would let a clinic bill for NAD+ administration in a covered way are not consistently recognized for elective wellness protocols. The result, in practice:

• Major medical: No coverage in the routine case
• HSA accounts: Generally no coverage without a specific qualifying medical diagnosis on the prescription
• FSA accounts: Mixed — some FSA administrators accept NAD+ when prescribed for fatigue or post-illness recovery, others do not
• Concierge or direct-care plans: Sometimes included, depending on the practice

The narrow exceptions where insurance has reimbursed NAD+ tend to involve a specific qualifying diagnosis — alcohol-use disorder withdrawal protocols are the most common precedent — that does not generalize to wellness use.

For most patients, NAD+ is paid for out of pocket, in both formats. That is the baseline cost comparison the rest of this article assumes.

Where the cost difference actually comes from

The structural reasons telehealth subcutaneous comes in cheaper than clinic IV are not about the active ingredient. They are about everything else stacked on top of it.

Facility overhead. A clinic IV requires a clinic — exam space, infusion chairs, biohazard handling, certifications, rent. A subcutaneous protocol shipped to the patient does not.

Per-session nursing labor. A clinic IV requires a nurse to start the line, monitor the infusion, and discontinue. That is 60 to 90 minutes of skilled labor per session. A self-administered subcutaneous injection takes the patient 90 seconds and requires no clinical labor at the time of injection.

Compounding complexity. Subcutaneous formulations are less complex to prepare than IV bags. Single-use vials or pre-filled syringes cost less to produce, ship, and store than multi-bag IV protocols.

Inventory and waste. IV bags expire on shorter timelines than refrigerated subcutaneous vials in most formulations. Clinics that stock IV NAD+ accept some inventory waste; telehealth pharmacies fill against patient prescriptions and waste less.

The active nicotinamide adenine dinucleotide itself is a small fraction of either total cost. Most of the price difference is structural.

Per-milligram value comparison

A simple per-milligram comparison clarifies the math:

• Clinic IV at $500 for 750 mg: roughly $0.67 per milligram, with no ongoing clinician contact between sessions
• Telehealth subcutaneous at $350 monthly for 800 mg across 8 sessions: roughly $0.44 per milligram, with included clinician oversight

The per-milligram cost is consistently 30 to 50 percent lower in the subcutaneous telehealth format. That ratio holds across most regions and tiers.

Two caveats matter, though. First, the milligrams are not pharmacokinetically identical. An IV bolus produces a sharp peak the subcutaneous route does not match. Second, the clinical question is not always per-milligram — sometimes it is per-event.

When IV makes sense anyway

Despite the cost gap, there are clinical situations where the IV format is the right choice:

• Single-event recovery. A patient recovering from a defined event — a competition, a long international flight, a surgical procedure — may benefit from a single high-dose IV bolus that the subcutaneous protocol cannot replicate inside one session.
• Patients who cannot self-inject. Some patients are not candidates for self-administration. The clinic IV is the format for them.
• Acute presentations. Patients with severe fatigue presentations or specific recovery situations where the clinician judges a sharp peak is clinically preferable to steady-state.

These cases are real, and they are the cases where the higher per-session cost reflects clinical value rather than structural overhead.

When subcutaneous is the better fit

For most patients pursuing NAD+ for ongoing recovery, sleep architecture, training response, and energy support, subcutaneous is the format that fits the goal at the cost most patients can sustain over six to twelve months.

The clinical reason is steady-state exposure. Recovery and sleep effects build over weeks of consistent dosing, and the subcutaneous schedule supports that continuity at a cost most patients can budget for indefinitely. A patient who would do twelve clinic IV sessions across a year at $500 each is spending $6,000; the same patient on a $300 monthly telehealth program spends $3,600 with eight times the dosing frequency.

The cost compounds in the opposite direction the longer the protocol runs.

How TelePeptide handles this

NAD+ subcutaneous protocols are priced at the locked-in founder rate inside the Foundation track. The flat monthly fee includes the clinician onboarding visit, prescription, compounded medication from a licensed 503A pharmacy, supplies, and ongoing clinician check-ins. There is no per-session billing.

Patients whose clinical situation calls for an IV format are referred to local clinic partners; the telehealth program is not a replacement for in-person care when in-person care is what fits.

Compounded medications are prepared by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.